William Blair Issues Positive Estimate for TMDX Earnings

TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) - Equities research analysts at William Blair boosted their Q1 2025 EPS estimates for shares of TransMedics Group in a research report issued to clients and investors on Tuesday, October 29th. William Blair analyst R. Daniels now expects that the company will post earnings of $0.35 per share for the quarter, up from their prior estimate of $0.34. The consensus estimate for TransMedics Group's current full-year earnings is $1.22 per share. William Blair also issued estimates for TransMedics Group's Q2 2025 earnings at $0.44 EPS.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its quarterly earnings results on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing analysts' consensus estimates of $0.29 by ($0.17). TransMedics Group had a net margin of 0.84% and a return on equity of 15.98%. The firm had revenue of $108.76 million for the quarter, compared to analysts' expectations of $115.00 million. During the same quarter last year, the firm earned ($0.12) earnings per share. The firm's revenue for the quarter was up 63.7% on a year-over-year basis.

Several other research firms have also recently weighed in on TMDX. Stephens upped their price objective on shares of TransMedics Group from $151.00 to $178.00 and gave the stock an "overweight" rating in a research report on Friday, August 2nd. Robert W. Baird decreased their price target on shares of TransMedics Group from $200.00 to $150.00 and set an "outperform" rating on the stock in a report on Tuesday. Piper Sandler reaffirmed an "overweight" rating and set a $180.00 price objective on shares of TransMedics Group in a report on Tuesday. JPMorgan Chase & Co. reduced their target price on TransMedics Group from $173.00 to $116.00 and set an "overweight" rating on the stock in a research note on Tuesday. Finally, Oppenheimer dropped their price target on TransMedics Group from $200.00 to $125.00 and set an "outperform" rating for the company in a research note on Tuesday. One equities research analyst has rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, TransMedics Group currently has an average rating of "Buy" and an average price target of $144.80.

TransMedics Group Price Performance

NASDAQ TMDX traded down $6.58 during trading on Wednesday, reaching $81.92. The company's stock had a trading volume of 4,524,838 shares, compared to its average volume of 931,404. The firm has a fifty day moving average of $146.02 and a 200 day moving average of $140.16. TransMedics Group has a one year low of $36.42 and a one year high of $177.37. The stock has a market capitalization of $2.73 billion, a PE ratio of 90.30 and a beta of 1.99. The company has a debt-to-equity ratio of 2.67, a current ratio of 9.37 and a quick ratio of 8.48.

Institutional Investors Weigh In On TransMedics Group

Institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. lifted its stake in TransMedics Group by 2.8% in the fourth quarter. Vanguard Group Inc. now owns 1,865,115 shares of the company's stock worth $147,214,000 after acquiring an additional 50,673 shares during the period. Allspring Global Investments Holdings LLC lifted its position in shares of TransMedics Group by 3.1% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 730,010 shares of the company's stock worth $53,977,000 after purchasing an additional 21,737 shares during the period. Oak Ridge Investments LLC raised its stake in TransMedics Group by 59.5% in the first quarter. Oak Ridge Investments LLC now owns 18,267 shares of the company's stock worth $1,351,000 after buying an additional 6,813 shares in the last quarter. BNP Paribas Financial Markets raised its stake in TransMedics Group by 35.1% in the first quarter. BNP Paribas Financial Markets now owns 17,390 shares of the company's stock worth $1,286,000 after buying an additional 4,518 shares in the last quarter. Finally, Fidelis Capital Partners LLC purchased a new stake in TransMedics Group in the first quarter worth about $35,000. Hedge funds and other institutional investors own 99.67% of the company's stock.

Insider Transactions at TransMedics Group

In related news, insider Tamer I. Khayal sold 2,958 shares of the stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $156.77, for a total transaction of $463,725.66. Following the completion of the sale, the insider now directly owns 20,843 shares in the company, valued at $3,267,557.11. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other news, Director Edward M. Basile sold 6,750 shares of the company's stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $149.96, for a total transaction of $1,012,230.00. Following the completion of the transaction, the director now directly owns 732 shares of the company's stock, valued at approximately $109,770.72. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Tamer I. Khayal sold 2,958 shares of the firm's stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $156.77, for a total value of $463,725.66. Following the completion of the sale, the insider now directly owns 20,843 shares in the company, valued at $3,267,557.11. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 64,205 shares of company stock worth $9,981,907. Company insiders own 7.00% of the company's stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.